Physician profile
Lior Koppel
NPI 1356492789
$1,437.39
in general payments reported to CMS, 2019-2025
13 companies · $486 in 2025
The $486 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $336 · 2021: $38.81 · 2022: $204 · 2024: $175 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $268.32 | 2019-2024 | Misight Contact Lens |
| Visioneering Technologies, INC. | $248.53 | 2019-2025 | |
| Genzyme Corporation | $191.30 | 2022-2025 | |
| Biotissue Holdings INC. | $177.23 | 2024-2025 | |
| Alcon Vision LLC | $104.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $92.90 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $82.00 | 2019-2025 | |
| Abbvie INC. | $81.19 | 2024 | |
| Allergan, INC. | $73.32 | 2020-2022 | |
| Ivantis, INC | $62.50 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $18.99 | 2024 | Xdemvy |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lior Koppel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.